Take Action

Your actions make a difference. Take a stand for the future of medicine.

We can’t advance patient-centered innovation alone. Join us in our fight to protect patient access to medications and treatments and support the next generation of medical breakthroughs.

Insert Link:

Tell Your Representative: Cosponsor and Pass H.R. 6283 and Stand Up to Prescription Drug Middlemen

Lawmakers are working on bipartisan legislation that addresses some of the abusive practices pharmacy benefit managers (PBMs) use to pad their profits at the expense of patients.
Insert Link:
Picture of Congress Building

Urge Your Senators to Stand Up to Drug Middlemen and Cosponsor and Pass S. 1542

Lawmakers are working on bipartisan legislation that addresses some of the abusive practices pharmacy benefit managers (PBMs) use to pad their profits at the expense of patients. PBMs work with insurance companies to decide what medicines patients can get and how much people pay out of pocket. We need your help to keep up the pressure on Congress to pass strong PBM reform this year.
Insert Link:

Protect Innovation and Jobs

Tell Congress to Protect American Jobs from Foreign Competitors

Urge Your Senators to Stand Up to Drug Middlemen and Cosponsor and Pass S. 1542

Lawmakers are working on bipartisan legislation that addresses some of the abusive practices pharmacy benefit managers (PBMs) use to pad their profits at the expense of patients.

PBMs work with insurance companies to decide what medicines patients can get and how much people pay out of pocket.

We need your help to keep up the pressure on Congress to pass strong PBM reform this year.

Just three PBMs control 80% of the market. They rely on opaque business practices that experts warn can lead to higher costs for patients.

For example, they collect exorbitant fees tied to the price of medicines, which means they can benefit more from preferring higher-price medicines, even though that may mean higher costs for patients.

A recent analysis found the share of PBM profits from these fees paid by pharmacies, employers and other entities increased 300% over the last decade.

To rein in these powerful middlemen, Democrat and Republican senators have introduced the Delinking Revenue from Unfair Gouging Act (S. 1542).

The bill would end incentives that experts have noted may drive PBMs to prefer higher-priced medicines when cheaper versions are available. Instead, PBMs would be required to charge flat fees based on the services they provide, making the system more competitive, transparent and affordable.

As momentum grows in Congress to address PBM abuses, middlemen are doing everything they can to stop these commonsense changes. According to one media report, the PBM industry is spending record amounts on lobbying to defeat these reforms. That’s why we need your help.

Time is running out to hold these middlemen accountable. Contact your U.S. Senators today and urge them to cosponsor and pass S. 1542. By building support for the bill, you can help make sure strong PBM reform legislation passes this year.

Protect Innovation and Jobs

Tell Congress to Protect American Jobs from Foreign Competitors

The World Trade Organization (WTO) is considering eliminating requirements that China, India and other countries protect American intellectual property (IP) for COVID-19 treatments. This would mean that local companies in foreign countries could use the IP of American scientists without their permission to make and sell copycat COVID-19 treatments.

President Biden can stop the WTO from allowing this to happen. Both Democrats and Republicans in Congress have encouraged the Biden Administration to intervene at the WTO. The U.S. should not allow these countries to push their proposal – referred to as “TRIPS waiver expansion.”

• Both President Biden and the World Health Organization have declared that the COVID-19 public health emergency is over. 

• There is a global surplus of affordable and often free COVID-19 treatments.

• There is no need to produce copycat medicines abroad.

American leadership and global collaboration has succeeded in defeating COVID-19, with voluntary agreements providing access to treatments across the globe. Expansion of the TRIPS waiver would harm global health and America’s global competitiveness, economic and job security.

The Biden Administration must reject TRIPS waiver expansion and protect American jobs.